Lupin gets EIR from US FDA for Nagpur-based injectable facility

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

05 February 2026 16:01:00

Adani Ports

1565.95

(-0.07%)

Asian Paints

2431.75

(-0.85%)

Axis Bank

1332.10

(-0.47%)

Bajaj Finance

964.70

(0.11%)

Bajaj Finserv

2006.70

(-0.62%)

Bharat Electro..

432.85

(-1.42%)

Bharti Airtel

1992.05

(-1.65%)

Eternal

286.90

(-2.50%)

HCL Technologi..

1608.80

(-0.83%)

HDFC Bank

949.50

(-0.41%)

Hind. Unilever

2354.00

(-0.73%)

ICICI Bank

1396.20

(-0.89%)

Infosys

1519.80

(-1.05%)

Interglobe Avi..

4933.95

(-0.60%)

ITC

310.25

(-1.15%)

Kotak Mah. Ban..

411.50

(-0.17%)

Larsen & Toubr..

4060.20

(-0.64%)

M & M

3570.55

(-0.09%)

Maruti Suzuki

15004.30

(-0.49%)

NTPC

366.90

(-0.11%)

Power Grid Cor..

289.25

(-0.03%)

Reliance Indus..

1443.40

(-0.91%)

SBI

1073.40

(0.50%)

Sun Pharma.Ind..

1702.30

(-0.10%)

Tata Steel

197.65

(1.23%)

TCS

2992.05

(-0.26%)

Tech Mahindra

1643.80

(-0.07%)

Titan Company

4101.65

(-0.84%)

Trent

4131.60

(2.95%)

UltraTech Cem.

12750.00

(-0.41%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Lupin gets EIR from US FDA for Nagpur-based injectable facility	Share Back
(17 Dec 2025)
The EIR was issued following an inspection of the facility from 08 September 2025 to 16 September 2025. Nilesh Gupta, managing director, Lupin, said: “We are pleased to have received the EIR from the U.S. FDA with a VAI classification for our Nagpur injectable facility. We are committed to upholding the highest standards of quality and compliance across our facilities, with continued focus on enhancements to our quality systems and operational excellence.” Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025. The counter rose 0.84% to currently trade at Rs 2107.20 on the BSE.
Top